4 citations
,
August 2010 in “Acta Biologica Hungarica” This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.
45 citations
,
September 2000 in “Archives of dermatology” This study found that 5alpha-reductase type 1 localizes specifically to sebaceous glands in both normal and acne follicles, suggesting its role in sebum regulation.
56 citations
,
December 2002 in “The Journal of Clinical Endocrinology & Metabolism” This study suggests that in human osteoblast-like cells, the 5alpha-reductase type 1 isozyme predominantly catalyzes the conversion of testosterone to DHT, which may play a role in bone homeostasis.
December 2023 in “International Journal of Molecular Sciences” In this study, researchers found that young men with androgenic alopecia exhibited significantly higher mRNA levels of 5α-reductase isozymes and changes in prostate cancer-related genes, which could explain varying responses to treatment and guide future therapies.